AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15845678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 9
Study 12692006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12692006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 14
Study 10588412 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient commitment
Number of subjects: 264
Study 10588412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment
Number of subjects: 264
Study 10588412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment with higher intensity of outpatient treatment
Number of subjects: 264
Study 10588412 — intervention group
Group type: COMPARATOR
Intervention: Control group (released subjects)
Number of subjects: 264
Study 8537594 — intervention group
Group type: EXPERIMENTAL
Intervention: A.G.E. dementia care program
Number of subjects: 81
Study 8537594 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing home care (Control)
Number of subjects: 81
Study 1681722 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 47
Study 1681722 — intervention group
Group type: COMPARATOR
Intervention: No Heparin
Number of subjects: 47
Study 6759144 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg
Number of subjects: 0
Study 6759144 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 0
Study 6759144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31537880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactavira (SOF 400mg/DCV 60mg/EGCG 400mg)
Number of subjects: 72
Study 31537880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactavira plus (SOF 400mg/DCV 60mg/EGCG 400mg/RBV 800mg)
Number of subjects: 72
Study 31537880 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOF 400mg/DCV 60mg)
Number of subjects: 72
Study 31537880 — intervention group
Group type: COMPARATOR
Intervention: Standard of care + RBV (SOF 400mg/DCV 60mg/RBV 800mg)
Number of subjects: 72
Study 31537880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactavira or Dactavira plus
Number of subjects: 72
Study 28488080 — intervention group
Group type: EXPERIMENTAL
Intervention: PBB-VPC
Number of subjects: 28
Study 28488080 — intervention group
Group type: EXPERIMENTAL
Intervention: PBB-HPH
Number of subjects: 28
Study 28488080 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 25428511 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric imbrication (LGI)
Number of subjects: 30
Study 25428511 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 30
Study 24611484 — intervention group
Group type: EXPERIMENTAL
Intervention: UP446 (500 mg/day)
Number of subjects: 79
Study 24611484 — intervention group
Group type: COMPARATOR
Intervention: naproxen (440 mg/day)
Number of subjects: 79
Study 22143314 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full weight bearing
Number of subjects: 37
Study 22143314 — intervention group
Group type: COMPARATOR
Intervention: Partial weight bearing for three months
Number of subjects: 37
Study 19272084 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation
Number of subjects: 97
Study 19272084 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation (attendees)
Number of subjects: 97
Study 19272084 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study 17239062 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based stroke prevention programme (eight weekly two-hour sessions)
Number of subjects: 190
Study 17239062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study 15057896 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous catheter drainage (8F multi‐sidehole pigtail catheter)
Number of subjects: 64
Study 15057896 — intervention group
Group type: COMPARATOR
Intervention: Intermittent needle aspiration (18G disposable trocar needle)
Number of subjects: 64
Study 12500884 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin prophylaxis
Number of subjects: 0
Study 9585772 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum antimicrobial therapy and operation
Number of subjects: 429
Study 7896992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg) available to all participants
Number of subjects: 3923
Study 7896992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum use at 12 months
Number of subjects: 3923
Study 7896992 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater social and environmental support for quitting smoking
Number of subjects: 3923
Study 7896992 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline variables associated with initial quitting
Number of subjects: 3923
Study 7896992 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking at least 1 cigarette between quit day and 4 months
Number of subjects: 3923
Study 2172376 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min of bicycle exercise three times per week at 60‐70% of maximum work for 12 weeks
Number of subjects: 10
Study 629073 — intervention group
Group type: EXPERIMENTAL
Intervention: mepindolol-sulfate
Number of subjects: 5
Study 629073 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 5
Study 30548890 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation Planning, Recording and Summarising (CPRS)
Number of subjects: 0
Study 30548890 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28541285 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of opioidergic circuit
Number of subjects: 0
Study 28541285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological challenge of opioid receptor function
Number of subjects: 0
Study 25872507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20) with twirling at 60 times per minute toward the contralateral outer canthus at a depth of 0.5 to 0.8 cun
Number of subjects: 144
Study 25872507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20) with twirling at 60 times per minute toward the Adam's apple at a depth of 0.5 to 0.8 cun
Number of subjects: 144
Study 25872507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20) with twirling at 120 times per minute toward the contralateral outer canthus at a depth of 0.5 to 0.8 cun
Number of subjects: 144
Study 25872507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20) with twirling at 120 times per minute toward the Adam's apple at a depth of 0.5 to 0.8 cun
Number of subjects: 144
Study 23637069 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy programme for care home staff to increase activity provision
Number of subjects: 210
Study 23637069 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 21113789 — intervention group
Group type: EXPERIMENTAL
Intervention: NW + 0.5 kg
Number of subjects: 12
Study 21113789 — intervention group
Group type: EXPERIMENTAL
Intervention: NW + 1.5 kg
Number of subjects: 12
Study 21113789 — intervention group
Group type: EXPERIMENTAL
Intervention: NW
Number of subjects: 12
Study 21113789 — intervention group
Group type: COMPARATOR
Intervention: W
Number of subjects: 12
Study 19594087 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g CHO in 400 ml of water
Number of subjects: 200
Study 19594087 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g aspartam in 100 ml of water (Control)
Number of subjects: 200
Study 16772250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 103
Study 16772250 — intervention group
Group type: COMPARATOR
Intervention: Health Education (Control)
Number of subjects: 103
Study 15487740 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-imaging-weighted equivalent uniform dose (fEUD) calculation using FDG-PET activity as a surrogate for tumor cell density
Number of subjects: 31
Study 15487740 — intervention group
Group type: COMPARATOR
Intervention: Equivalent uniform dose (EUD) calculation assuming uniform tumor cell density
Number of subjects: 31
Study 11598557 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol with oxytocin infusion
Number of subjects: 90
Study 11598557 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 90
Study 9440361 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for visual target location over a range of 4-30 seconds
Number of subjects: 0
Study 9440361 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding of a second location presented sequentially
Number of subjects: 0
Study 7700063 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril 1-5 mg once daily for 12 weeks
Number of subjects: 1163
Study 7700063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 0.5-15 mg once daily
Number of subjects: 1163
Study 7700063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril therapy
Number of subjects: 1163
Study 3038254 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily for 6 months
Number of subjects: 20
Study 3038254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31952073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP (b-CPAP) bundle of care
Number of subjects: 773
Study 31952073 — intervention group
Group type: COMPARATOR
Intervention: Initial management with CPAP
Number of subjects: 773
Study 29632227 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement materials developed through Boot Camp Translation (BCT) involving community members, practice members, and public health professionals.
Number of subjects: 0
Study 29632227 — intervention group
Group type: COMPARATOR
Intervention: Standard practice facilitation support
Number of subjects: 0
Study 27013483 — intervention group
Group type: EXPERIMENTAL
Intervention: PlayForward videogame intervention
Number of subjects: 333
Study 27013483 — intervention group
Group type: COMPARATOR
Intervention: Control games
Number of subjects: 333
Study 25639570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 36
Study 25639570 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered therapy (PCT)
Number of subjects: 36
Study 25639570 — intervention group
Group type: EXPERIMENTAL
Intervention: High treatment responders (collapsed across treatments)
Number of subjects: 36
Study 25639570 — intervention group
Group type: EXPERIMENTAL
Intervention: High treatment responders (mid-treatment)
Number of subjects: 36
Study 25639570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts of incompetence (high treatment responders)
Number of subjects: 36
Study 25639570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts of a dangerous world (high treatment responders)
Number of subjects: 36
Study 25639570 — intervention group
Group type: EXPERIMENTAL
Intervention: Script-associated cortisol response prior to treatment and reductions in thoughts of incompetence
Number of subjects: 36
Study 23413013 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory imagery self-report questionnaire (Bucknell Auditory Imagery Scale)
Number of subjects: 0
Study 23413013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch discrimination task
Number of subjects: 0
Study 21920193 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized counseling on contraceptive acceptability
Number of subjects: 246
Study 21920193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personalized counseling)
Number of subjects: 246
Study 18487911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with radiotherapy
Number of subjects: 0
Study 18487911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with 5-FU and cisplatin
Number of subjects: 0
Study 18487911 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 18487911 — intervention group
Group type: COMPARATOR
Intervention: 5-FU and cisplatin alone
Number of subjects: 0
Study 17057622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound monitoring of the cycle alone
Number of subjects: 0
Study 17057622 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring including hormone assays and ultrasound
Number of subjects: 0
Study 12745440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersensory paired‐preference procedure
Number of subjects: 0
Study 12419788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber supplement (13.5 g/day)
Number of subjects: 0
Study 12419788 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber supplement (2.0 g/day)
Number of subjects: 0
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy change due to inadequate blood pressure control
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy change due to adverse effects
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy change due to patient dissatisfaction
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy change due to non-compliance
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy change due to cost
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects reported by physicians
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient compliance assessment
Number of subjects: 1603
Study 10321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-compliance as assessed by patients
Number of subjects: 1603
Study 7706963 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine fortified fish sauce
Number of subjects: 0
Study 7706963 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated salt
Number of subjects: 0
Study 7706963 — intervention group
Group type: COMPARATOR
Intervention: Control (Ban Non Sa‐aad)
Number of subjects: 0
Study 2691818 — intervention group
Group type: EXPERIMENTAL
Intervention: Body hair removal (EXP group)
Number of subjects: 9
Study 2691818 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 9
Study 5082546 — intervention group
Group type: EXPERIMENTAL
Intervention: Erect position
Number of subjects: 0
Study 5082546 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study 27644137 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3-rich enteral nutrition (900 mg of ω-3 fatty acids)
Number of subjects: 61
Study 27644137 — intervention group
Group type: COMPARATOR
Intervention: ω-3-poor enteral nutrition (250 mg of ω-3 fatty acids)
Number of subjects: 61
Study 25245781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen bone allograft (FFB) combined with bovine bone mineral (BBM) at a 2:1 ratio
Number of subjects: 29
Study 25245781 — intervention group
Group type: COMPARATOR
Intervention: Allograft bone (control group)
Number of subjects: 29
Study 23359310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (4.5 mg/day)
Number of subjects: 31
Study 23359310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21062392 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg/day for 6 weeks
Number of subjects: 82
Study 21062392 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 82
Study 19926556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist‐provided intervention to improve heart failure medication adherence
Number of subjects: 314
Study 19926556 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 17493465 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PPCI)
Number of subjects: 2781
Study 17493465 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 2781
Study 17493465 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI
Number of subjects: 2781
Study 15792021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane for laryngeal mask insertion (LMI)
Number of subjects: 30
Study 15792021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane for tracheal intubation (TI)
Number of subjects: 30
Study 11302464 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternated basketball
Number of subjects: 32
Study 11302464 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternated running
Number of subjects: 32
Study 11302464 — intervention group
Group type: COMPARATOR
Intervention: Control, adapted physical activity
Number of subjects: 32
Study 11302464 — intervention group
Group type: COMPARATOR
Intervention: Control, sedentary
Number of subjects: 32
Study 10374274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (Flu) 200-400 mg daily for 1-8 weeks
Number of subjects: 222
Study 10374274 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (Keto) 400 mg daily for 1-8 weeks
Number of subjects: 222
Study 10374274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (Flu) in open trial (150 mg single dose for fungal vaginitis)
Number of subjects: 222
Study 7885486 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically-designed nursing practice model
Number of subjects: 0
Study 7885486 — intervention group
Group type: COMPARATOR
Intervention: Control unit
Number of subjects: 0
Study 7885486 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental unit
Number of subjects: 0
Study 3330526 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ‐A 39 (falipamil), 2 mg kg‐1
Number of subjects: 10
Study 3330526 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 0.1 mg kg‐1
Number of subjects: 10
Study 3330526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3330526 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ‐A 39 (falipamil)
Number of subjects: 10
Study 3330526 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 31164277 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin
Number of subjects: 98
Study 31164277 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly cisplatin
Number of subjects: 98
Study 31364232 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 10
Study 31364232 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA + Teduglutide
Number of subjects: 10
Study 31364232 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + Teduglutide
Number of subjects: 10
Study 31364232 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA + Placebo
Number of subjects: 10
Study 31556273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetero-Rituximab (test)
Number of subjects: 40
Study 31556273 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (Roche, reference)
Number of subjects: 40
Study 25769495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor inhibitor strategy
Number of subjects: 432
Study 25769495 — intervention group
Group type: COMPARATOR
Intervention: Combined disease modifying drug strategy
Number of subjects: 432
Study 23394263 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (ertapenem 1 g per day for 3 days, followed by oral levofloxacin 500 mg per day and metronidazole 1.5 g per day for 7 days)
Number of subjects: 610
Study 23394263 — intervention group
Group type: COMPARATOR
Intervention: Emergency appendectomy
Number of subjects: 610
Study 23394263 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 610
Study 21936253 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 50
Study 21936253 — intervention group
Group type: COMPARATOR
Intervention: AO tubular external fixation
Number of subjects: 50
Study 20047114 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 42
Study 20047114 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 42
Study 20047114 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 42
Study 17154642 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy (starting dose of 10-15 mg/m2/week orally, increased to 15-20 mg/m2/week parenterally)
Number of subjects: 0
Study 17154642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with methotrexate and an NSAID
Number of subjects: 0
Study 17154642 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/day)
Number of subjects: 0
Study 17154642 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily folate supplementation
Number of subjects: 0
Study 15701229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with VM lesions
Number of subjects: 15
Study 15701229 — intervention group
Group type: COMPARATOR
Intervention: Brain-damaged comparison subjects
Number of subjects: 15
Study 15701229 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 15
Study 12580112 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablet of potassium chloride (2 g)
Number of subjects: 18
Study 12580112 — intervention group
Group type: COMPARATOR
Intervention: Common tablet of potassium chloride (2 g)
Number of subjects: 18
Study 12580112 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment
Number of subjects: 18
Study 9240183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 2% lignocaine gel for 25 min
Number of subjects: 150
Study 9240183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 2% lignocaine gel for 15 min
Number of subjects: 150
Study 9240183 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricating gel for 5 min
Number of subjects: 150
Study 9240183 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricating gel for 25 min
Number of subjects: 150
Study 9240183 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of 2% lignocaine gel for 5 min
Number of subjects: 150
Study 8252507 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen blockade (orchiectomy + nilutamide)
Number of subjects: 457
Study 8252507 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy alone (placebo)
Number of subjects: 457